Patrick A. Baeuerle, Ph.D., Professor for Immunology, Senior Vice President, Chief Scientific Officer, Micromet, Inc.
Mr. Baeuerle has served as Micromet's Chief Scientific Officer since October 1998. From February 1996 to September 1998, Mr. Baeuerle headed the drug discovery activities of Tularik Inc. in South San Francisco, CA, as Director, Drug Discovery. From October 1994 to February 1996, Mr. Baeuerle served as a full Professor and Chairman of Biochemistry at the Medical Faculty of Freiburg University, Germany. In 1989, he was awarded a group leader position at the Gene Center in Martinsried, Germany, where he did seminal research on transcription factor NF-kappaB. According to a survey by the Institute for Scientific Information (ISI, Philadelphia, PA, USA), Mr. Baeuerle was Germany's most frequently cited biomedical scientist of the past decade, and 38th worldwide. He has published more than 200 scientific papers, and four educational children books on biology. In addition, Mr. Baeuerle is the first recipient of the Prix Européen de l'Avenir and an elected member of the European Molecular Biology Organization (EMBO). He was appointed Honorary Professor of Immunology at the University of Munich in 2000. Mr. Baeuerle performed his Ph.D. work at the Max Planck Institute for Psychiatry in Martinsried and at the European Molecular Biology Laboratory (EMBL) in Heidelberg, obtained a Ph.D. degree in biology from the University of Munich, and performed his post-doctoral research with David Baltimore at the Whitehead Institute of the Massachusetts Institute of Technology (MIT), Cambridge, MA.
David M. Goldenberg, M.D., President, Garden State Cancer Center; CSO & CMO, Immunomedics, Inc.
Dr. David M. Goldenberg is President of the Garden State Cancer Center and the Center for Molecular Medicine and Immunology, a specialized cancer research center located in Morris Plains, New Jersey. He has also been Adjunct Professor of Microbiology and Immunology at New York Medical College, Valhalla, New York, and Adjunct Professor of Medicine and Surgery at New Jersey Medical School, UMDNJ, and is one of the recognized pioneers in the field of cancer imaging and therapy with monoclonal antibodies, which he coined as radioimmunodetection and radioimmunotherapy. He is also the Founder and Chairman of Immunomedics, Inc., a publicly-traded biopharmaceutical company also located in Morris Plains, NJ, as well as its majority-owned subsidiary, IBC Pharmaceuticals, Inc. Born in Brooklyn, New York, Dr. Goldenberg received his S.B. degree from the University of Chicago, Division of Biological Sciences in December 1958. He received his M.D. degree, magna cum laude, from the University of Heidelberg School of Medicine in Germany in 1966, and his Sc.D. degree, cum laude, from the University of Erlangen-Nuremberg Faculty of Natural Sciences, Germany in 1965. In 1968, Dr. Goldenberg returned to the USA to the position of Associate Research Professor of Pathology, University of Pittsburgh School of Medicine, and Staff Pathologist at the VA Hospital, in Pittsburgh, Pennsylvania (1970-72).
In 1972, he moved to Kentucky where he was appointed Professor of Pathology and Director of Experimental Pathology at the University of Kentucky. In Kentucky, he was also the founder and first President of the University’s first Cancer Research Center. In 1979, he took a sabbatical leave at the Immunology Branch Division of Cancer Biology and Diagnosis, National Cancer Institute, NIH, in Bethesda, Maryland. Dr. Goldenberg moved to New Jersey in 1983 to become President of the Center for Molecular Medicine and Immunology/Garden State Cancer Center, his current post.
During his career, Dr. Goldenberg has written or co-authored approximately 1,700 journal articles, abstracts and book chapters on cancer immunology and other topics of cancer research. He has served on the editorial boards for numerous journals, including Journal of Cancer Research and Clinical Oncology, Cancer, Cancer Research, Tumor Targeting, Tumor Biology, Journal of Nuclear Medicine, and American Journal of Blood Research.
In recognition of his research contributions, Dr. Goldenberg was given the University of Kentucky Research Foundation Award in 1978, a Silver Medallion and Certificate from the German Fund for Cancer Research in Bonn in 1979, an “Outstanding Investigator Award” grant from the National Cancer Institute in 1985 and 1992, and the New Jersey Pride Award in Science and Technology in 1986. He was also cited by a Resolution of Commendation of the New Jersey General Assembly and the New Jersey Senate in 1985/86. Dr. Goldenberg was honored as the ninth Otto Herz Lecturer of Tel Aviv University Faculty of Life Sciences. In addition, he received the 1991 3M Mayneord Memorial Award and Lectureship of the British Institute of Radiology for his contributions to the development of radiolabeled antibodies used in the imaging and treatment of cancer. Dr. Goldenberg was the co-recipient of the 1994 Abbott Award, sponsored by the International Society of Oncodevelopmental Biology and Medicine, the recipient of the 1994 Sarabhai Memorial Oration Award, sponsored by the Society of Nuclear Medicine, India, and the 2002 Erin Berven Prize recipient and Lecturer of the Swedish Oncology Society, including a medal from the Swedish Medical Society. In 2003, he received the Garden State Cancer Center Award for Special Scientific Achievements, and in 2004 he received the Distinguished Scientist Award of the Clinical Ligand Assay Society. In 2005, Dr. Goldenberg received the Paul C. Aebersold Award, the highest recognition given by the Society of Nuclear Medicine for contributions to the basic sciences with applications to the practice of nuclear medicine. Also in 2005, he was named Inventor of the Year by The Research and Development Council of New Jersey for being the recipient of over 180 U.S. and foreign patents, particularly in the area of applying monoclonal antibodies to the detection and treatment of various diseases.
Horst Lindhofer, Ph.D., Founder & CEO, TRION Pharma GmbH
Dr. Horst Lindhofer, CEO and founder of TRION Pharma GmbH, received his PhD at the Ludwig-Maximilians-University (LMU), Munich, in 1992 for his work on examination on maturation and assembly of HIV-1 with specific antibodies. After having spent several years as research scientist at GSF Institute of Immunology, he was appointed Head of Clinical Co-operation Group “bispecific antibodies in tumor therapy” of the Department of Otorhinolaryngology, LMU Munich, and GSF Institute of Clinical Molecular Biology and Tumour Genetics, Munich.
TRION Pharma GmbH, founded by Dr. Lindhofer in 1998, is a privately held biopharmaceutical company that has established a novel approach to cancer immunotherapy. The Company’s unique family of trifunctional antibodies, called Triomab®, simultaneously activates multiple immune defense mechanisms against cancer.In spring 2009, Removab® (catumaxomab) received EU approval for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas. It is marketed by TRION’s partner Fresenius Biotech.
Ulrich Brinkmann, Ph.D., Scientific Director, Biologics Engineering, Roche Pharma Research and Early Development
Dr. Ulrich Brinkmann heads a Protein Engineering unit within Roche Pharma Research in Penzberg, FRG. His Ph.D thesis covered development of expression systems to produce recombinant reteplase. Subsequently, he held positions as Postoc and Associate Scientist at the NIH/NCI (Ira Pastan Lab) focusing on antibody stabilization/engineering and recombinant immunotoxins for cancer therapy. Prior to joining Roche, he served as CSO in Functional Genetics and Pharmacogenetics companies, Xantos and Epidauros (now Beckmann Coulter) respectively.
Wei Yan, Ph.D., Director, Research, Protein Science, Amgen, Inc.
Dr. Wei Yan is the Director of Research at Amgen Seattle site where he currently leads the Antibody Technology Group. Since joining Amgen (formerly Immunex) in 2001, Dr. Yan and his co-workers have been working on developing protein based therapeutics for cancer and inflammatory diseases. Prior to Amgen, Dr. Yan was a Scientist in Cardiovascular Research Unit at Bayer Schering Pharma (formerly Berlex Bioscience) where he discovered corin, the proatrial natriuretic peptide (proANP) converting enzyme. Wei received his Ph.D. in molecular and cell biology from the joint program of Cornell University Medical College and Memorial Sloan Kettering Cancer Center in New York City and his B.S. degree in cell biology and genetics from Peking University in Beijing, China.
Nico Mertens, Ph.D., Director, Antibody Engineering, Biotecnol SA
Dr. Nico Mertens obtained his Ph.D. in Biotechnology with Dr. Walter Fiers (University of Gent, Belgium) on protein expression technology. After several years in post-doctoral positions, Dr. Mertens headed the Molecular Immuno-Biotechnology Unit at the Flanders Institute of Biotechnology (VIB), where he conceived and developed the Tribody antibody fragment design, which later on became co-owned and exclusively licensed from VIB to Biotecnol.
Dr. Mertens obtained his MBA from EMS Brussels in 2002 and created and headed VIB’s Protein Service Facility, which delivered profitable services in protein engineering, expression, purification and characterization for internal and external clients, including several large pharma companies. Dr. Mertens was an active member of several university and professional committees and responsible for teaching courses and training students in Molecular Biotechnology at Ghent University. He is author of 25 international peer reviewed articles and 4 patent applications on technology to be applied in protein production and antibody engineering.
Paul W.H.I. Parren, Ph.D., Senior Vice President and Scientific Director, Genmab AS
Dr. Paul Parren has been working in the field of recombinant antibodies for 25 years. He holds a PhD in molecular immunology from the University of Amsterdam (1992). Dr. Parren was an Associate Professor at The Scripps Research Institute in La Jolla, California, where he worked between 1993 and 2002 on studying the role of human antibodies in protection against viral infections. In 2002, he joined Genmab where he is currently a member of the senior management team. Dr. Parren serves in the position of Senior Vice President and Scientific Director. He leads the Genmab Utrecht site and is responsible for Genmab’s Research and Pre-Clinical Development.
Dr. Parren has a strong expertise in antibody biology and immunotherapy and is particularly interested in unraveling the mechanisms by which antibodies act in vivo, and applying this knowledge to the development of novel antibody therapeutics. Dr. Parren has published extensively both in the scientific as well as the patent literature. Currently, his studies focus on antibody structure-function relationships, antibody-drug conjugates, bispecific antibodies and the development of innovative immunotherapeutics in cancer. He is an inventor of the CD20 antibody ofatumumab (Arzerra) which became a licensed therapeutic in the US in 2009 and EU in 2010. Recently, Arzerra won the Netherlands 2011 Galenus prize for most innovative and meaningful new therapeutic.